ストックスクリーナーアプリを入手
23.83
2.32%
0.54
プレマーケット:
23.50
-0.33
-1.38%
Urogen Pharma Ltd (URGN) 最新ニュース
UroGen outlines $1B peak revenue goal for ZUSDURI amid accelerated adoption and expanded pipeline - MSN
UroGen earnings in focus: Can ZUSDURI drive commercial momentum? - Investing.com
Understanding Momentum Shifts in (URGN) - Stock Traders Daily
Urogen Pharma (URGN) Projected to Post Quarterly Earnings on Wednesday - MarketBeat
UroGen Pharma : 2025 Annual Report - marketscreener.com
UroGen Pharma (NASDAQ: URGN) seeks approvals on board, equity plan and bylaws - Stock Titan
UroGen Pharma to Report First Quarter 2026 Financial Results on Wednesday, May 6th, 2026 - ChartMill
BlackRock (URGN) discloses 2.52M shares, 5.2% stake reported - Stock Titan
HC Wainwright Predicts Urogen Pharma Q1 Earnings - MarketBeat
Urogen Pharma Ltd at TD Cowen Healthcare Conference Transcript - GuruFocus
Urogen Pharma (NASDAQ:URGN) Rating Increased to Strong-Buy at Jefferies Financial Group - MarketBeat
HC Wainwright Predicts Urogen Pharma Q3 Earnings - MarketBeat
Avoiding Lag: Real-Time Signals in (URGN) Movement - Stock Traders Daily
URGN Stock Price, Quote & Chart | UROGEN PHARMA LTD (NASDAQ:URGN) - ChartMill
UroGen Pharma (URGN) Stock: Trending Up? (Gains) 2026-04-22Certified Trade Ideas - Cổng thông tin điện tử Tỉnh Sơn La
UroGen Pharma Ltd. (URGN) - Minichart
Piper Sandler Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Maintains Target Price $40 - Moomoo
Urogen Pharma (NASDAQ:URGN) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
UroGen Pharma Ltd stock (IL0011408896): Is its urology focus strong enough to unlock new upside? - AD HOC NEWS
UroGen Pharma (URGN) Stock: Momentum Analysis (Momentum Building) 2026-04-18Diversification - Xã Thanh Hà
UroGen Pharma Ltd. (NASDAQ: URGN) seeks 1,000,000-share plan increase - Stock Titan
UroGen Pharma Ltd | PRE 14A: Preliminary proxy statements relating to merger or acquisition - Moomoo
Market Pulse: Is now the right time to enter UroGen Pharma LtdPortfolio Growth Summary & Fast Entry High Yield Tips - baoquankhu1.vn
Discipline and Rules-Based Execution in URGN Response - Stock Traders Daily
URGN INVESTOR NOTICE: UroGen Pharma Ltd. Investors with Substant - GuruFocus
UroGen Pharma (URGN) Is Up 14.6% After Phase 3 ENVISION Data And LG-UTUC Outreach Push - Sahm
URGN SEC FilingsUrogen Pharma 10-K, 10-Q, 8-K Forms - Stock Titan
Urogen Pharma (NASDAQ:URGN) Shares Gap UpTime to Buy? - MarketBeat
Jefferies Initiates UroGen Pharma Ltd(URGN.US) With Buy Rating, Announces Target Price $40 - 富途牛牛
Can UroGen Pharma (URGN) Stock Recover Now | URGN Q4 Earnings: Misses Estimates by $0.03Real Time Stock Idea Network - Xã Thanh Hà
UroGen Launches LG-UTUC Luminaries Initiative Recognizing Excellence and Leadership in Treatment of Patients with Low-Grade Upper Tract Urothelial Cancer - Sahm
UroGen Pharma Ltd. Launches LG-UTUC Luminaries Initiative Recognizing Excellence and Leadership in Treatment Of Patients with Low-Grade Upper Tract Urothelial Cancer - marketscreener.com
UroGen Launches LG-UTUC Luminaries Initiative Recognizing - GlobeNewswire
Trend Report: Will UroGen Pharma Ltd stock benefit from M AEarnings Growth Summary & Low Volatility Stock Suggestions - baoquankhu1.vn
Bull Bear: What are the risks of holding UroGen Pharma LtdWeekly Profit Summary & Weekly Setup with High ROI Potential - baoquankhu1.vn
Trend Recap: Is UroGen Pharma Ltd a cyclical or defensive stock2026 Reactions & Weekly High Conviction Trade Ideas - baoquankhu1.vn
Why The UroGen Pharma (URGN) Investment Story Is Shifting As Analysts Hold Fair Value Steady - Yahoo Finance
URGN Stock Analysis: UroGen Pharma Ltd. Ordinary Shares dips 0.63% to hold $18.82 price level - Cổng thông tin điện tử tỉnh Lào Cai
UroGen Pharma CMO Schoenberg sells $145k in shares - Investing.com
UroGen Pharma Ltd.Ordinary Shares (NQ: URGN - The Chronicle-Journal
UroGen Pharma Ltd (UR8.DU) Income Statement - ca.finance.yahoo.com
Behavioral Patterns of URGN and Institutional Flows - Stock Traders Daily
Activity Recap: Will UroGen Pharma Ltd stock benefit from M AMarket Volume Summary & Precise Entry and Exit Recommendations - baoquankhu1.vn
URGN: D. Boral Capital Maintains Buy Rating with $33 Price Targe - GuruFocus
Urogen Pharma's (URGN) Buy Rating Reaffirmed at D. Boral Capital - MarketBeat
Hennion & Walsh Asset Management Inc. Boosts Stock Position in Urogen Pharma $URGN - MarketBeat
UroGen’s Zusduri shows 72% event-free rate at 24 months By Investing.com - Investing.com South Africa
UroGen Pharma (URGN) Announces Positive Phase 3 Trial Results fo - GuruFocus
UroGen’s Zusduri shows 72% event-free rate at 24 months - Investing.com
Urogen Pharma Ltd. Publishes ENVISION Trial Results Showing 72.2% 24-Month Duration of Response with ZUSDURI - marketscreener.com
Journal of Urology Publishes ENVISION Trial Results Showing 72.2% 24-Month Duration of Response with ZUSDURI - GlobeNewswire
0.14%
0.48%
大文字化:
|
ボリューム (24 時間):